Date: Tuesday, June 4, 2019
Session Time: 2:30pm-4:00pm
Presentation Time: 2:30pm-2:42pm
Location: Veterans Auditorium
*Purpose: Galectin-3 has been associated with renal fibrosis and decline of renal function. We aimed to determine the association of galectin-3 with long-term risk of death-censored graft failure in a large cohort of extensively phenotyped renal transplant recipients (RTR).
*Methods: We performed a longitudinal cohort study in 561 RTR with a functioning graft ≥1 year, recruited between 2001 and 2003 in a university setting. Galectin-3 levels were determined in serum samples (BG Medicine, Inc, Waltham, MA). Death-censored graft failure was defined as restart of dialysis or re-transplantation. Cox-proportional hazards regression analyses were performed to assess the association of galectin-3 with outcome.
*Results: Baseline median galectin-3 was 21.1 [interquartile range, 17.0‒27.2] ng/mL. During a median follow-up of 6.9 [6.2-7.5] years, 53 RTR developed graft failure. In multivariable-adjusted Cox regression analysis, galectin-3 was associated with death-censored graft failure (hazard ratio, 2.32 per 1-SD increase; 95% confidence interval, 1.68 to 3.20, P<0.001), independent of well-established general and renal transplant-specific risk factors, including estimated Glomerular Filtration Rate and proteinuria.
*Conclusions: In RTR, galectin-3 is elevated and independently associated with long-term risk of death-censored graft failure. Galectin-3 may be helpful to assess prognosis and guide existing therapy. Whether a novel galectin-3-targeted therapy may represent an opportunity to decrease the burden of long-term graft failure in stable RTR requires further studies.
|Model||Gal-3, per 1─SD increase|
|Model 1||2.42 (1.90-3.07)||<0.001|
|Model 2||2.32 (1.68-3.20)||<0.001|
|Model 3||2.56 (1.79-3.65)||<0.001|
|Model 4||2.14 (1.51-3.04)||<0.001|
|Model 1: crude. Model 2: adjustment for recipient age, sex and BMI, donor age and sex, dialysis vintage, type of transplant, time since transplantation time-dependent eGFR and proteinuria. Model 3: model 2 + immunosuppressive therapy. Model 4: model 2 + cardiovascular risk factors.|
To cite this abstract in AMA style:Sotomayor CG, Keyzer CA, Anderson JL, Gans RO, Nolte IM, Borst MHde, Berger SP, Navis GJ, Boer RAde, Bakker SJ. Galectin-3 and Long-Term Graft Failure in Renal Transplant Recipients: A Prospective Cohort Study [abstract]. Am J Transplant. 2019; 19 (suppl 3). https://atcmeetingabstracts.com/abstract/galectin-3-and-long-term-graft-failure-in-renal-transplant-recipients-a-prospective-cohort-study/. Accessed January 19, 2022.
« Back to 2019 American Transplant Congress